Immunotherapy for Colorectal Cancer: A Changing Landscape

For years,patients diagnosed with colorectal cancer received a consistent answer to the question,”Could immunotherapy be an option for me?” That answer was,unequivocally,no. However,a growing body of evidence from both basic and clinical research indicates this response is no longer accurate. While historically ineffective, immunotherapy is now demonstrating potential benefits for a subset of colorectal cancer patients.

The past 15 years have witnessed a revolution in oncology driven by immunotherapy. This progress has been highlighted by landmark clinical trials, significant media coverage, and recognition with three Nobel Prizes. This stands in stark contrast to the frequently enough-negative public perception surrounding chemotherapy.

Why the shift? Traditionally, colorectal cancers were considered “cold” tumors – meaning they lacked the immune cell infiltration necessary for immunotherapy to be effective. Most colorectal cancers are characterized by a low mutational burden and a lack of microsatellite instability (MSI). MSI-High (MSI-H) tumors, representing approximately 15% of colorectal cancers, do respond to immunotherapy. These tumors have a higher mutation rate, leading to the production of neoantigens that can stimulate an immune response.

Understanding MSI and dMMR

Microsatellite instability (MSI) refers to a change in the length of DNA sequences called microsatellites. This happens when the mismatch repair (MMR) system isn’t working correctly.dMMR (deficient mismatch repair) means the cancer cells have defects in these MMR genes. Both MSI-H and dMMR tumors are more likely to respond to immunotherapy as they have more mutations, making them more visible to the immune system. Testing for MSI and MMR deficiency is now standard practice for colorectal cancer diagnosis.

Current Immunotherapy Approaches

The primary immunotherapy drugs used in colorectal cancer treatment are checkpoint inhibitors. These drugs, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), block proteins that prevent the immune system from attacking cancer cells. They have shown significant efficacy in patients with MSI-H/dMMR colorectal cancer. The National Complete Cancer Network (NCCN) guidelines recommend pembrolizumab for first-line treatment of metastatic MSI-H/dMMR colorectal cancer. NCCN Guidelines

Beyond MSI-H/dMMR: Future Directions

Research is actively exploring ways to extend the benefits of immunotherapy to patients with microsatellite stable (MSS) or proficient mismatch repair (pMMR) colorectal cancers, which comprise the majority of cases. Strategies under examination include:

• Combination Therapies: Combining immunotherapy with chemotherapy, targeted therapies, or radiation therapy to enhance the immune response.
• Vaccines: Developing vaccines to stimulate an immune response against specific cancer antigens.
• Fecal Microbiota Transplantation (FMT): Altering the gut microbiome to improve immunotherapy response.
• Oncolytic Viruses: Using viruses to selectively infect and kill cancer cells, triggering an immune response.

What This Means for Patients

The evolving landscape of immunotherapy offers new hope for patients with colorectal cancer. If you have been diagnosed with colorectal cancer, discussing your MSI/MMR status and the potential for immunotherapy with your oncologist is crucial. Even if your tumor is not MSI-H/dMMR, ongoing clinical trials may offer access to innovative immunotherapy approaches.

Resources:

• National Cancer Institute – Colorectal Cancer
• Cancer Research UK – Colorectal Cancer
• colorectal Cancer Alliance

Publication Date: 2025/11/19 16:54:24